Vogenx (NASDAQ:VOGX) Shares Climb 8.7% – Here’s Why

Vogenx Inc (NASDAQ:VOGX)’s stock price was up 8.7% on Wednesday. The company traded as high as $22.24 and last traded at $20.39. 84,314 shares traded hands during mid-day trading, a decline of 14% from the average daily volume of 97,768 shares. The stock had previously closed at $18.75.

Wall Street Analysts Forecast Growth

VOGX has been the subject of a number of research analyst reports. JonesTrading started coverage on shares of Vogenx in a research note on Tuesday, September 1st. They issued a “buy” rating and a $55.00 price target for the company. Wall Street Zen upgraded shares of Vogenx to a “hold” rating in a research report on Saturday, August 22nd. Zacks Research upgraded shares of Vogenx to a “hold” rating in a report on Monday, September 28th. Finally, WBB Securities began coverage on shares of Vogenx in a research report on Wednesday, September 2nd. They issued a “speculative buy” rating and a $42.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $48.50.

Vogenx Trading Down 8.5%

The company has a fifty day moving average of $25.00. The firm has a market capitalization of $259.13 million and a P/E ratio of -249.29.

Vogenx (NASDAQ:VOGX) last issued its quarterly earnings results on Thursday, September 17th. The company reported ($0.07) earnings per share for the quarter. As a group, equities analysts expect that Vogenx Inc will post -0.61 earnings per share for the current fiscal year.

Vogenx Company Profile

Vogenx, Inc is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. The company has historically concentrated on small-molecule drug candidates intended to address conditions in which existing treatment options may be limited.

Vogenx’s lead development program has included VGX-1027, an investigational anti-inflammatory compound studied for its potential to regulate abnormal immune responses. Research involving the candidate has focused on diseases associated with inflammation and immune-system dysfunction, although its development status and commercial availability may change over time.

The company’s activities have primarily involved pharmaceutical research and development rather than the marketing of an established portfolio of products.